» Articles » PMID: 24830600

HDAC 1/4-mediated Silencing of MicroRNA-200b Promotes Chemoresistance in Human Lung Adenocarcinoma Cells

Overview
Journal Oncotarget
Specialty Oncology
Date 2014 May 17
PMID 24830600
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Chemoresistance is one of the most significant obstacles in lung adenocarcinoma (LAD) treatment, and this process involves genetic and epigenetic dysregulation of chemoresistance-related genes. Previously, we have shown that restoration of microRNA (miR)-200b significantly reverses chemoresistance of human LAD cells by targeting E2F3. However, the molecular mechanisms involved in the silencing of miR-200b are still unclear. Here we showed that histone deacetylase (HDAC) inhibitors could restore the expression of miR-200b and reverse chemoresistant phenotypes of docetaxel-resistant LAD cells. HDAC1/4 repression significantly increased miR-200b expression by upregulating histone-H3 acetylation level at the two miR-200b promoters partially via a Sp1-dependent pathway. Furthermore, silencing of HDAC1/4 suppressed cell proliferation, promoted cell apoptosis, induced G2/M cell cycle arrest and ultimately reversed in vitro and in vivo chemoresistance of docetaxel-resistant LAD cells, at least partially in a miR-200b-dependent manner. HDAC1/4 suppression-induced rescue of miR-200b contributed to downregulation of E2F3, survivin and Aurora-A, and upregulation of cleaved-caspase-3. HDAC1/4 levels in docetaxel-insensitive human LAD tissues, inversely correlated with miR-200b, were upregulated compared with docetaxel-sensitive tissues. Taken together, our findings suggest that the HDAC1/4/Sp1/miR-200b/E2F3 pathway is responsible for chemoresistance of docetaxel-resistant LAD cells.

Citing Articles

HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond.

Minisini M, Mascaro M, Brancolini C Cancer Drug Resist. 2024; 7:46.

PMID: 39624079 PMC: 11609180. DOI: 10.20517/cdr.2024.103.


Hypoxia-Inducible Factor-Dependent and Independent Mechanisms Underlying Chemoresistance of Hypoxic Cancer Cells.

Lee P, Koseki L, Haitani T, Harada H, Kobayashi M Cancers (Basel). 2024; 16(9).

PMID: 38730681 PMC: 11083728. DOI: 10.3390/cancers16091729.


Composition of Conditioned Media from Radioresistant and Chemoresistant Cancer Cells Reveals miRNA and Other Secretory Factors Implicated in the Development of Resistance.

Molodtsova D, Guryev D, Osipov A Int J Mol Sci. 2023; 24(22).

PMID: 38003688 PMC: 10671404. DOI: 10.3390/ijms242216498.


Research progress on the utilization technology of broccoli stalk, leaf resources, and the mechanism of action of its bioactive substances.

Yan L, Zhou G, Shahzad K, Zhang H, Yu X, Wang Y Front Plant Sci. 2023; 14:1138700.

PMID: 37063225 PMC: 10090291. DOI: 10.3389/fpls.2023.1138700.


The role of miR-200 family in the regulation of hallmarks of cancer.

Klicka K, Grzywa T, Mielniczuk A, Klinke A, Wlodarski P Front Oncol. 2022; 12:965231.

PMID: 36158660 PMC: 9492973. DOI: 10.3389/fonc.2022.965231.


References
1.
Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff M . CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J Clin Invest. 2013; 123(6):2395-407. PMC: 3668829. DOI: 10.1172/JCI66553. View

2.
Pulikkan J, Peramangalam P, Dengler V, Ho P, Preudhomme C, Meshinchi S . C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood. 2010; 116(25):5638-49. PMC: 3031410. DOI: 10.1182/blood-2010-04-281600. View

3.
Wang Q, Chen W, Bai L, Chen W, Padilla M, Lin A . Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway. J Biol Chem. 2014; 289(9):5654-63. PMC: 3937640. DOI: 10.1074/jbc.M113.526152. View

4.
Wendtner C . Cocktail of eternity: HDAC meets miR. Blood. 2012; 119(5):1095-6. DOI: 10.1182/blood-2011-12-394494. View

5.
Fulciniti M, Amin S, Nanjappa P, Rodig S, Prabhala R, Li C . Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011; 17(20):6500-9. PMC: 4318245. DOI: 10.1158/1078-0432.CCR-11-1036. View